Proof of Concept Application of Hydrophilic Interaction
Chromatography for Direct Online Disruption of Lipid Nanoparticles,
Intact mRNA Analysis, and Measure of Encapsulation Efficiency
posted on 2025-04-01, 12:16authored byJonathan Maurer, Matthew A. Lauber, Szabolcs Fekete, Mateusz Imiołek, Camille Malburet, Marc François-Heude, Davy Guillarme
Lipid nanoparticles (LNPs) are a key platform for delivering mRNA
vaccines and therapeutics with numerous innovative drugs under development.
However, characterizing these complex and unstable products remains
challenging. Developing fast, reliable methods to assess critical
quality attributes (CQAs) of the mRNA component is crucial for ensuring
the safety and efficacy of these medicines. Currently, evaluating
key CQAs, such as mRNA integrity and encapsulation efficiency, often
involves a labor-intensive manual extraction protocol, which requires
LNP disruption prior to analysis. However, these additional offline
steps contribute to mRNA degradation and measurement uncertainties,
highlighting the urgent need for rapid and effective methods capable
of performing an online LNP disruption. Hydrophilic interaction chromatography
(HILIC) might offer a promising solution to address this need. Due
to the presence of high concentrations of organic solvent and the
possibility to work at elevated temperatures, HILIC might enable on-column
disruption of LNPs while preserving the full integrity of the mRNA
payload, facilitating a streamlined characterization process. To evaluate
this, we developed two proof of concept HILIC methods. The first one
disrupts LNPs and retains the mRNA payload using a high percentage
of organic solvent and elevated temperatures. The second one, relying
on milder conditions, retains only the unencapsulated mRNA, which
can be used to evaluate the encapsulation efficiency. Both methods
were used on Comirnaty and Spikevax vaccines and on Sanofi’s
in-development mRNA product as model samples. Our preliminary findings
suggest that HILIC holds potential for online LNP disruption, mRNA
integrity assessment, and encapsulation efficiency analysis. They
also highlight the limitations of small-pore-sized columns currently
available on the market.